# of Patients 300K Total trial eligible patient prevalence Today, treated with topical steroids and/or oral immunosuppressants 1 Contraindicated for intraocular steroids Today, treated with single intraocular steroid injection Treated with multiple intraocular steroid injections Refractory to intraocular steroids 1L (4-6 weeks) 2L (~3 months) 3L (6+ months) Note: 1 First line includes eye drops or systemic immunnosuppressants. Eyedrops prescribed by physicians includes steroidal and non-steroidal anti-inflammatory drops; IO = Intraocular; ME = Macular Edema; MESI = Macular Edema Secondary to Inflammation; Source: Bellocq et al., BMJ (2014); Birnbaum et al., JAMA Ophthalmol. (2011); Erden et al., Ocular Immunol. Inflamm. (2019); Kao et al., A.A. Ophthalmol. (2022);Expert Interviews (JUN 2025); MUST Research Group, Ophthalmol. (2019); Schallhorn et al., Am. J. Ophthalmol. (2018) KSI-101 initial addressable population is >150,000 KSI-101 initial addressable population is greater than 150,000 MESI patients in the US Example therapies: KSI-101 ADDRESSABLE POPULATION Total MESI prevalence 455K 298K 34K 153K 25K 157K 16K 70K Minus Acute post- procedural and infectious >150,000 97